Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 17/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23548752 | 0.85 | EIF2AK4 (0.68) | EIF2AK4 | |
| SCHEMBL23548753 | 0.85 | EIF2AK4 (0.68) | EIF2AK4 | |
| SCHEMBL23548335 | 0.84 | EIF2AK4 (0.63) | EIF2AK4 | |
| SCHEMBL23548742 | 0.84 | EIF2AK4 (0.76) | EIF2AK4 | |
| SCHEMBL23548570 | 0.84 | EIF2AK4 (0.76) | EIF2AK4 | |
| SCHEMBL23548673 | 0.84 | EIF2AK4 (0.53) | EIF2AK4 | |
| SCHEMBL23548449 | 0.84 | EIF2AK4 (0.62) | EIF2AK4 | |
| SCHEMBL23548645 | 0.84 | EIF2AK4 (0.57) | EIF2AK4 | |
| SCHEMBL23548906 | 0.83 | EIF2AK4 (0.50) | EIF2AK4 | |
| SCHEMBL23548702 | 0.83 | EIF2AK4 (0.53) | EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | GLS, GLS2, TK2 | EIF2AK4 1089/4885MAPK14 3097/4885CDK1 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.